12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Company News  |  Deals

Quest Diagnostics, Trovagene deal

Trovagene granted Quest a non-exclusive license to use nucleophosmin ( NPM1; B23) in research and clinical testing services related to acute myelogenous leukemia (AML)....

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >